AXL and soft tissue sarcoma: The sarcoma cohort was included based on the known intrinsically high expression of AXL in these tumors as well as preclinical studies that showed EnaV was able to elicit antitumor activity in patient-derived xenograft models of soft-tissue sarcoma (17).